GCM
LGND icon

Geneva Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Geneva Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-392,416
Closed -$17.8M – 122
2020
Q1 		$17.8M Buy
+392,416
New +$22.2M 0.51% 78

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Geneva Capital Management's LGND Position: Q2 2020 in Review

Geneva Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2020, closing a stake of 392,416 shares — an estimated $17.8M sold.

Geneva Capital Management first reported a position in LGND in Q1 2020 and held it in 1 quarter. The position peaked at $17.8M in Q1 2020. 262 funds tracked by Wall St. Rank hold LGND as of Q2 2020.

  • Geneva Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Geneva Capital Management sold 392,416 Ligand Pharmaceuticals shares in Q2 2020, an estimated $17.8M.
  • Geneva Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Geneva Capital Management's Ligand Pharmaceuticals position peaked at $17.8M in Q1 2020.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2020.

Based on Geneva Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.